Abstract: A printed circuit board assembly includes a first printed circuit board, a second printed circuit board disposed on the first printed circuit board and including an antenna pattern, a third printed circuit board disposed on the first printed circuit board, one or more first electronic components disposed between the first and the second printed circuit board and electrically connected to at least one of the first and the second printed circuit board, one or more second electronic components disposed between the first and the third printed circuit board, and electrically connected to at least one of the first and the third printed circuit board, a first interposer substrate electrically connecting the first printed circuit board and the second printed circuit board to each other, and a second interposer substrate electrically connecting the first printed circuit board and the third printed circuit board to each other.

Abstract: The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure shows high luminous efficiency and good lifespan by comprising a specific combination of the plural kinds of host compounds and a specific hole transport compound.

Abstract: Provided is a method for recovering and reusing an active material from a positive electrode scrap.

Abstract: The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure shows high luminous efficiency and good lifespan by comprising a specific combination of the plural kinds of host compounds and a specific hole transport compound.

Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnosis agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.

Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.

Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnosis agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.

Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnotic agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.

Abstract: The present invention relates to immune stimulating composition comprising methylated bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.

Abstract: The present invention relates to a method for preparing microvesicular ADAM15, comprising: (a) a step of activating protein kinase C (PKC) of separated mammalian cells; and (b) a step of separating microvesicle-containing ADAM15 from the mammalian cells. According to the present invention, a method for preparing microvesicular ADAM15 from mammalian cells is provided, and a novel cell regulation mechanism mediated by ADAM proteins is provided by the study of the function of the microvesicular ADAM15. Further, the present invention may provide a novel anti-cancer drug using microvesicular ADAM15, which inhibits adhesion, proliferation and migration of tumor cells.

Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.

Abstract: Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.

Abstract: Disclosed is the therapeutic use of CpG oligodeoxynucleotides for skin diseases. The CpG oligodeoxynucleotides (CpG ODNs) of the present invention show excellent immunoactive effects against skin diseases in both cases of CpG ODNs with a phosphorothioate backbone and CpG ODNs with a phosphodiester backbone.

Abstract: Disclosed are oligonucleotides for manipulating an immune reaction. The oligonucleotides of the present invention may be useful to stimulate the immune function, to treat the immune-related diseases and the atopic dermatitis, or to protect the normal immune cells.

Abstract: Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.

Abstract: The present invention relates to a linkage system and a linkage method that links an e-mail address with a postal address. The present invention relates to a system and a method that delivers a postal item to a real address of a customer corresponding to an e-mail address, even though the e-mail address is entered in the postal item. According to the present invention, since the e-mail address and the postal address are linked with each other, even if the user's residence is changed, the changed address can be confirmed by using the e-mail address that is linked with the postal address. Accordingly, it is possible to prevent the loss of the postal item. In addition, since a semi-permanent e-mail address is used instead of the postal address, which often changes, in a communication way between individuals, a sender can send the postal item by using only the e-mail address without worrying about the address change of recipient, even when not knowing the address of the recipient.

Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight crosslinked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and a method for manufacturing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnosis agent for screening and detecting in vivo D-dimer, and high molecular weight crosslinked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and crosslinked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.

Abstract: Disclosed is a composition for treating vascular diseases by acting on abnormal angiogenesis by means of secretion of angiopoietins.

Abstract: The present invention relates to immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysacchararides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant.

Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.